GLP-1 Medications in Australia: Ozempic vs Wegovy vs Mounjaro vs Saxenda (2026)

Mounjaro (tirzepatide) currently has the strongest published weight-loss outcomes (SURMOUNT-1 trial: ~21% mean body weight loss at 72 weeks, highest dose). Wegovy (semaglutide 2.4mg) had the previous benchmark (STEP-1 trial: ~14.9%). Both are weekly subcutaneous injections. Ozempic (semaglutide 1mg/2mg) is the same active ingredient as Wegovy at lower doses, primarily indicated for type 2 diabetes — but commonly prescribed off-label for weight loss before Wegovy became available.

Ozempic IS on the PBS — but ONLY for type 2 diabetes patients with confirmed HbA1c above thresholds. Under PBS Authority Streamlined, T2D patients pay $31.60/month general script ($7.70 concession) for Ozempic — vastly cheaper than the $330–$450/month private price for Wegovy/Mounjaro. The medication cost is similar; the difference is PBS subsidy. Wegovy + Mounjaro are NOT on the PBS for weight loss as at January 2026 — patients pay full private price.

Yes — but you pay the private price ($150-$250/month script), not the PBS-subsidised $31.60. Many doctors prescribe Ozempic off-label for weight loss. However, since 2023 there have been Australia-wide shortages of Ozempic 1mg + 2mg pens, with TGA prioritising supply for T2D patients on PBS. Wegovy (the official weight-loss-indication version of semaglutide) became widely available in Australia in 2024 — most weight-loss prescribers now prescribe Wegovy or Mounjaro rather than off-label Ozempic.

PBS Authority Streamlined for semaglutide (Ozempic) requires the patient to have type 2 diabetes + HbA1c above specified thresholds + documented prior treatment with metformin (and typically one other oral agent or a second-line consideration). The GP enters the streamlined code on the prescription; no phone authority required. If you have T2D, ask your GP to check PBS eligibility — the cost difference is huge ($30 vs $330+/month).

Most common (40-60% of patients in first 4 weeks): nausea, constipation, diarrhoea, fatigue, decreased appetite. Less common: gallstones (especially with rapid weight loss), pancreatitis (rare), gastroparesis (delayed gastric emptying), hair thinning (typically resolves). Medullary thyroid cancer warning is theoretical based on rodent data; large human studies have not shown increased risk. Most side effects are managed by slow dose titration + dietary changes (smaller meals, lower fat/sugar). About 5-15% of patients discontinue due to intolerable side effects.

Yes, most patients regain a significant portion. STEP-4 extension data showed approximately 2/3 of weight lost was regained within 12 months of stopping semaglutide without intensive lifestyle change. This is the major clinical question with GLP-1 therapy — patients typically need to remain on medication indefinitely OR transition to bariatric surgery for durable weight loss. Behavioural + dietary change during GLP-1 therapy is critical for maintenance.

Telehealth GLP-1 (Juniper, Mosh, Pilot, Compass) is convenient: complete online medical history → video consultation → script → medication shipped. Monthly subscription ~$290-$450 covers consult + script + admin. In-person GLP-1 clinics: comprehensive metabolic work-up (sleep study, full lipids, HbA1c, liver, comorbidity screening); same medication options; total cost similar. For patients with multiple comorbidities or complex history, in-person is preferable. For uncomplicated BMI 30-40 patients, telehealth is equally safe and clinically appropriate per current Australian practice.

Three pathways: (1) Your own GP can prescribe (Wegovy, Mounjaro, Saxenda, off-label Ozempic) — ask if comfortable. (2) Dedicated in-person medical weight-loss clinics — listed in our directory. (3) Telehealth platforms — Juniper, Mosh, Pilot, Compass dominate. Cost is similar across pathways (~$290-$450/month total). Your own GP is the cheapest for ongoing care if they're willing to prescribe. Telehealth is fastest to start. In-person clinics are best for comprehensive work-up.

GLP-1s are NOT first-line for type 1 diabetes — they're indicated for type 2. Some endocrinologists prescribe off-label in T1D adults with obesity, but it requires specialist supervision and careful insulin adjustment. Talk to an endocrinologist if you have T1D and weight management is a clinical priority.

No — GLP-1 medications are contraindicated in pregnancy + while trying to conceive. Both Wegovy + Mounjaro labels recommend discontinuing at least 2 months before conception (semaglutide has a half-life of ~7 days, with full clearance taking weeks). For women trying to conceive: stop GLP-1, allow 2-3 months washout, then start preconception care. Pregnancy itself often improves glycaemic control + metabolic state.